MedicaidPrior AuthLow impact
Asparlas™ (calaspargase pegol-mknl) (New)
Humana·IN · Oncology, Hematology, Pediatrics·Medicaid
Effective date
Dec 1, 2025
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Asparlas (calaspargase pegol-mknl) for Indiana Medicaid patients with acute lymphoblastic leukemia. Coverage requires patients be 21 years or younger, using the drug as part of multi-agent chemotherapy, with specific medical exclusions that may prevent approval.
Action Required
Before December 1, 2025: Billing team must obtain prior authorization for all Asparlas prescriptions for Indiana Medicaid patients. Verify patient meets criteria: diagnosis of ALL, age ≤21 years, multi-agent chemotherapy use, and absence of contraindications (prior serious reactions, thrombosis, pancreatitis, hemorrhage, or severe hepatic impairment). Initial approvals valid for 6 months.